A year ago, Astellas was celebrating the first-in-class approval of its claudin 18.2-targeting cancer drug Vyloy for gastric cancers. Now, a bid to expand its label into pancreatic cancer has hit the ...

Correspondence to Professor Tim J Gabbett, Gabbett Performance Solutions, Brisbane, QLD, Australia and University of Southern Queensland, Institute for Resilient Regions, Ipswich, QLD, Australia; ...